EXPLORE MORE CATEGORIES
- Home
- »
- Products & Services
- »
- Anti Cancer Tablets
Anti Cancer Tablets
We are a leading Wholesaler of paleno palbociclib 125mg tablet, lynparza olaparib 150 mf tablets and bevacizumab injection from Ahmedabad, India.
Paleno Palbociclib 125mg Tablet
Get Latest Price
Product Brochure
Product Details:
| Manufacturer | Sun Pharma |
| Treatment | Hr+ve ,Her2_ve locally ABC or MBC |
| Prescription/Non prescription | Prescription |
| Form | Tablet |
| Packaging Size | 1*21 Tablet Bottle |
| Brand | Paleno |
| Composition | Palbociclib |
A) For Women:
Palbociclib Paleno is indicated for the treatment of HR+, HER2- locally ABC or mBC:
- In combination with an AI
- In combination with fulvestrant in women who have received prior ET
In premenopausal or perimenopausal women, ET should be combined with an LHRH agonist.
Get Best QuoteRequest A Callback
Lynparza Olaparib 150 MF Tablets
Product Price: Rs 2.5 Lakh / BoxGet Best Price
Product Brochure
Product Details:
| Packaging Size | 7*8 Tablet |
| Manufacturer | Astra Zaneca |
| Treatment | BRCA 1/2 Mutation position Breast cancer , Prostate Cancer , Adenocarcinoma of Pancreas |
| Prescription/Non prescription | Prescription |
| Brand | Lynparza |
| Drug Name | Olaparib 150 MG Tablet |
| Dose/Strength | 150mg 2 Tablet |
| Usage/Application | Clinical |
| Form | Tablet |
Breast cancer
Lynparza is indicated as:
• monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).
• monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.
Adenocarcinoma of the pancreas
Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.
Prostate cancer
Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
Additional Information:
- Packaging Details: Breast cancer Lynparza is indicated as: • monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1). • monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy. Adenocarcinoma of the pancreas Lynparza is indicated as monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. Prostate cancer Lynparza is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
Get Best QuoteRequest A Callback
Bevacizumab Injection
Product Price: Get Latest Price
Get Best QuoteRequest A Callback